Stay updated with breaking news from Aim Immunotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AIM ImmunoTech Inc. (NYSE:AIM – Get Rating) traded down 4.2% on Friday . The company traded as low as $0.41 and last traded at $0.42. 93,307 shares were traded during trading, a decline of 64% from the average session volume of 256,005 shares. The stock had previously closed at $0.44. AIM ImmunoTech Stock Down 4.2 […]
The Securities and Exchange Commission’s (SEC’s) new universal proxy rules, which took effect for meetings after August 31, 2022, require the use of “universal” proxy cards in all...
The American Petroleum Institute has named Amanda Eversole its next chief advocacy officer.
AIM ImmunoTech (NYSE:AIM – Get Rating) and Icosavax (NASDAQ:ICVX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Institutional and Insider Ownership 15.6% of AIM ImmunoTech shares are […]
AIM ImmunoTech (NYSE:AIM – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04), Fidelity Earnings reports. AIM ImmunoTech had a negative net margin of 13,662.70% and a negative return on equity of 26.80%. Shares of NYSE […]